Skip to main content

REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells

  • Company: REPROCELL, Inc. (JASDAQ Company code: 4978)
  • Representative: Chikafumi Yokoyama, PhD
  • Contact:

We are pleased to announce that our company has entered into an exclusive licensing agreement with Keio University regarding myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells.

REPROCELL aims to establish commercial operations within the fiscal year by using state-of-the-art technology by which Keio University has reproduced the pathological state from iPS cells originating in patients with long QT syndrome, a congenital heart disease. Our business operations include ReproCardio2 cardiomyocytes derived from human iPS cells, and incorporating this technology will enable even greater differentiation. This commercial project will provide major impetus for progress in clarifying the long QT syndrome pathology and for new drug development, while further expanding our iPS cell business operations.

The REPROCELL group actively pursues progress in regenerative medicine based on the strengths of our world-leading ES/iPS cell technology and our global network. Beginning with this agreement, we aim to strengthen our ties with external research institutions in order to expand our business operations still further.

Note: About long QT syndrome

Long QT syndrome is a congenital heart disease that poses a risk of sudden death from arrhythmia. The name of the syndrome derives from the “QT” waveform on the electrocardiogram of patients, which is characteristically longer than for normal patients.

Subscribe to receive updates from REPROCELL